Innovative Test Enhances Quality Control in Allergy Treatments
A novel immunoassay developed by the Paul Ehrlich Institute allows precise measurement of allergoids in allergy medicines, improving quality control and standardization of allergy immunotherapy products.
A multidisciplinary team from the Allergology and Veterinary Medicine Divisions at the Paul Ehrlich Institute has developed a groundbreaking laboratory assay that allows for the precise quantification of adjuvanted allergoids within finished allergy medicinal products. Previously, assessing the content of these complex formulations was challenging due to their intricate structures, which contain both allergen-modifying compounds (allergoids) and adjuvants, restricting analysis to intermediary production stages. The newly introduced testing method marks a significant breakthrough in the quality assurance of allergy immunotherapy (AIT) medications.
Allergy immunotherapy involves using sensitized allergens to train the immune system towards tolerance, with allergoids being chemically modified allergens designed for this purpose. Accurate dosing and proven efficacy depend heavily on knowing the exact allergoid concentration, yet until now, this measurement in final pharmaceutical formulations was not feasible. The novel immunoassay employs highly specific antibodies in an enzyme-linked detection system, enabling accurate, reliable detection of allergoids directly in medicinal products. This method can effectively eliminate the need for animal testing and enhances the standardization and quality control processes.
The research, published in the journal "Allergy," demonstrates that this assay can consistently measure allergen content in grass pollen allergoids, which are common components in allergy therapy. The project was led by Dr. Frank Führer from the Paul Ehrlich Institute, emphasizing the importance of this advancement for regulatory oversight and manufacturing quality assurance. The implementation of such precise testing protocols promises to improve the consistency, safety, and efficacy of allergy treatments, benefiting both manufacturers and patients.
This development reinforces the Paul Ehrlich Institute's role in ensuring the safety and quality of allergy immunotherapies, responding to regulatory requirements by providing a sophisticated tool for batch testing and standardization. Source: https://medicalxpress.com/news/2025-06-quality-allergy-therapeutics.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Paper-Based Diagnostic Device Offers Rapid and Affordable Infectious Disease Detection
Researchers at NYU Abu Dhabi have developed a quick, affordable paper-based diagnostic tool capable of detecting infectious diseases like COVID-19 in under 10 minutes, ideal for resource-limited settings.
Electronic Consent Shows Promise to Address Key Barrier in Stroke Research Recruitment
Post-hoc analysis of a major stroke trial reveals that electronic informed consent enhances patient enrollment and compliance, addressing key barriers in stroke research recruitment.
Potential Health Risks from Metals in Ultrasonic Cigarettes
New research highlights health risks associated with ultrasonic cigarettes, revealing elevated levels of toxic metals in their liquids and aerosols that could pose serious long-term health dangers. Learn about the potential risks of this emerging vaping technology.
Implementing Road Emission Policies Could Save 1.9 Million Lives by 2040
Strategic policies targeting road transport emissions could save 1.9 million lives and prevent millions of asthma cases globally by 2040. Implementing vehicle standards and promoting clean electric transportation are key to improving public health worldwide.